Search:
Tokushima UniversityUniversity Hospital先端医科医療開発研究プロジェクト
Tokushima UniversityUniversity HospitalClinical DivisionDepartment of Internal MedicineHematology
Tokushima UniversityFaculty of MedicineSchool of MedicineCourse of Molecular MedicineHemotology, endocrinology and metabolism
(Files for researchmap) [PDF manual] [Auto-propagate to researchmap]

Research

Field of Study

Medicine

Subject of Study

Book / Paper

Book:

1. Kumiko Kagawa, 前田 悠作, Masahiro Oura, Kimiko Sogabe, 藤野 ひかる, 髙橋 真美子, 丸橋 朋子, 岩佐 昌美, 宇高 憲吾, Takeshi Harada, Takayuki Ise, Shiroh Fujii, Shingen Nakamura, Hirokazu Miki, Shusuke Yagi, Kyoko Takeuchi, Shuji Ozaki, Masahiro Abe and 藤野 ひかる :
Analysis of long-term survivors with cardiac AL amyloidosis,
The Japanese Society of Hematology, Oct. 2017.
(DOI: 10.11406/rinketsu.58.2197,   CiNii: 1390282680011466240)

Academic Paper (Judged Full Paper):

1. Kimiko Sogabe, Shingen Nakamura, Yoshiki Higa, Hirokazu Miki, Asuka Oda, Tomoko Maruhashi, Ryohei Sumitani, Masahiro Oura, Mamiko Takahashi, Masafumi Nakamura, Yusaku Maeda, Tomoyo Hara, Hiroki Yamagami, Shiroh Fujii, Kumiko Kagawa, Shuji Ozaki, Kiyoe Kurahashi, Itsuro Endo, Ken-ichi Aihara, Emiko Nakaue, Masahiro Hiasa, Jumpei Teramachi, Takeshi Harada and Masahiro Abe :
Acute accumulation of PIM2 and NRF2 and recovery of β5 subunit activity mitigate multiple myeloma cell susceptibility to proteasome inhibitors.,
International journal of hematology, Vol.119, No.3, 303-315, 2024.
(DOI: 10.1007/s12185-023-03705-9,   PubMed: 38245883)
2. Takeshi Harada, Hiroto Ohguchi, Asuka Oda, Michiyasu Nakao, Jumpei Teramachi, Masahiro Hiasa, Ryohei Sumitani, Masahiro Oura, Kimiko Sogabe, Tomoko Maruhashi, Mamiko Takahashi, Shiroh Fujii, Shingen Nakamura, Hirokazu Miki, Kumiko Kagawa, Shuji Ozaki, Shigeki Sano, Teru Hideshima and Masahiro Abe :
Novel antimyeloma therapeutic option with inhibition of the HDAC1-IRF4 axis and PIM kinase,
Blood Advances, Vol.7, No.6, 1019-1032, 2023.
(Tokushima University Institutional Repository: 118211,   DOI: 10.1182/bloodadvances.2022007155,   PubMed: 36129197)
3. Kimiko Nakano, Shiroh Fujii, Reiko Yamahana and Chiemi Onishi :
Motivation for physical activity before and after allogeneic hematopoietic stem cell transplantation.,
Blood Cell Therapy, Vol.6, No.1, 11-17, 2023.
(DOI: 10.31547/bct-2022-016,   PubMed: 37324566)
4. 高原 由実子, Hirokazu Miki, Shingen Nakamura, 林 成樹, Ryohei Sumitani, Masahiro Oura, Kimiko Sogabe, 髙橋 真美子, 丸橋 朋子, 富永 誠記, 岡本 秀樹, Naoto Okada, 矢野 由美子, 高橋 真理, 大坂 朱美, Takeshi Harada, Shiroh Fujii, Toshiyuki Suge, Keiko Aota, Shuji Ozaki and Masahiro Abe :
徳島県におけるHIV感染症および後天性免疫不全症候群患者の臨床的特徴と今後の課題,
Shikoku Acta Medica, Vol.78, No.5-6, 193-198, 2022.
(CiNii: 1050295181679877760)
5. Naoto Okada, Akikazu Murakami, Masami Satou, Shingen Nakamura, Shiroh Fujii, Kimiko Sogabe, Mamiko Takahashi, Asami Okada, Akane Abe, Hideki Fujii, Masahiro Abe, Momoyo Azuma and Keisuke Ishizawa :
First reported case of Lachnoanaerobaculum gingivalis bacteremia in an acute myeloid leukemia patient with oral mucositis during high dose chemotherapy.,
Anaerobe, Vol.76, 2022.
(DOI: 10.1016/j.anaerobe.2022.102610,   PubMed: 35811059)
6. Hiroki Yamada, Rio Ohmori, Naoto Okada, Shingen Nakamura, Kumiko Kagawa, Shiroh Fujii, Hirokazu Miki, Keisuke Ishizawa, Masahiro Abe and Youichi Sato :
A machine learning model using SNPs obtained from a genome-wide association study predicts the onset of vincristine-induced peripheral neuropathy,
The Pharmacogenomics Journal, 2022.
(Tokushima University Institutional Repository: 117583,   DOI: 10.1038/s41397-022-00282-8,   PubMed: 35752658)
7. Shin Kondo, Tatsuro Inoue, Takashi Saito, Yuka Kawamura, Ayane Katayama, Masafumi Nakamura, Ryohei Sumitani, Mamiko Takahashi, Masahiro Oura, Kimiko Sogabe, Takeshi Harada, Shiroh Fujii, Shingen Nakamura, Hirokazu Miki, Kumiko Kagawa, Nori Sato, Rei Ono, Masahiro Abe and Shinsuke Katoh :
Allogeneic haematopoietic stem cell transplantation and patient falls: impact of lower extremity muscle strength.,
BMJ Supportive & Palliative Care, 2022.
(DOI: 10.1136/bmjspcare-2022-003582,   PubMed: 35534187)
8. Minori Takei, Naoto Okada, Shingen Nakamura, Kumiko Kagawa, Shiroh Fujii, Hirokazu Miki, Keisuke Ishizawa, Masahiro Abe and Youichi Sato :
A genome-wide association study predicts the onset of dysgeusia due to anti-cancer drug treatment,
Biological & Pharmaceutical Bulletin, Vol.45, No.1, 114-117, 2022.
(Tokushima University Institutional Repository: 117584,   DOI: 10.1248/bpb.b21-00745,   PubMed: 34657909)
9. Shin Kondo, Kumiko Kagawa, Takashi Saito, Masahiro Oura, Kimiko Sogabe, Takeshi Harada, Shiroh Fujii, Shingen Nakamura, Hirokazu Miki, Nori Sato, Rei Ono, Masahiro Abe and Shinsuke Katoh :
Allogeneic haematopoietic stem cell transplantation-clinical outcomes: impact of leg muscle strength.,
BMJ Supportive & Palliative Care, 2021.
(DOI: 10.1136/bmjspcare-2021-003256,   PubMed: 34949601)
10. Jumpei Teramachi, Hirofumi Tenshin, Masahiro Hiasa, Asuka Oda, Ariunzaya Bat-Erdene, Takeshi Harada, Shingen Nakamura, Mohannad Ashtar, Sou Shimizu, Masami Iwasa, Kimiko Sogabe, Masahiro Oura, Shiroh Fujii, Kumiko Kagawa, Hirokazu Miki, Itsuro Endo, Tatsuji Haneji, Toshio Matsumoto and Masahiro Abe :
TAK1 is a pivotal therapeutic target for tumor progression and bone destruction in myeloma,
Haematologica, Vol.106, No.5, 1401-1413, 2021.
(Tokushima University Institutional Repository: 116529,   DOI: 10.3324/haematol.2019.234476,   PubMed: 32273474)
11. Ryohei Sumitani, Taiki Hori, Jumpei Murai, Shiyori Kawata, Masahiro Oura, Kimiko Sogabe, Mamiko Takahashi, Takeshi Harada, Shiroh Fujii, Hirokazu Miki, Kumiko Kagawa, Masahiro Abe and Shingen Nakamura :
Acute Myeloid Leukemia Developing with Acute Pancreatitis Mimicking Autoimmune Pancreatitis.,
Internal Medicine, Vol.60, No.11, 1753-1757, 2021.
(Tokushima University Institutional Repository: 116536,   DOI: 10.2169/internalmedicine.4916-20,   PubMed: 33456032)
12. Tashima Hozumi, Endo Yuka, Naoto Okada, Shingen Nakamura, Kumiko Kagawa, Shiroh Fujii, Hirokazu Miki, Keisuke Ishizawa, Masahiro Abe and Youichi Sato :
Association analysis between adverse drug reactions to cytarabine therapy and single nucleotide polymorphisms in cytarabine metabolic genes in patients with hematopoietic tumor,
Personalized Medicine Universe, Vol.10, 1-6, 2021.
(Tokushima University Institutional Repository: 117585,   DOI: 10.46459/pmu.2021002)
13. Mamiko Takahashi, Ryohei Sumitani, Taiki Hori, Jumpei Murai, Shiyori Kawata, Masahiro Oura, Kimiko Sogabe, Takeshi Harada, Shiroh Fujii, Hirokazu Miki, Kumiko Kagawa, Masahiro Abe and Shingen Nakamura :
Intravenous busulfan-based conditioning with autologous stem cell transplantation for refractory B-cell lymphoma with central nervous system involvement.,
The Journal of Medical Investigation : JMI, Vol.68, No.1.2, 196-201, 2021.
(Tokushima University Institutional Repository: 116021,   DOI: 10.2152/jmi.68.196,   PubMed: 33994471)
14. Mohannad Ashtar, Hirofumi Tenshin, Jumpei Teramachi, Ariunzaya Bat-Erdene, Masahiro Hiasa, Asuka Oda, Kotaro Tanimoto, Sou Shimizu, Yoshiki Higa, Takeshi Harada, Masahiro Oura, Kimiko Sogabe, Shingen Nakamura, Shiroh Fujii, Ryohei Sumitani, Hirokazu Miki, Kengo Udaka, Mamiko Takahashi, Kumiko Kagawa, Itsuro Endo, Eiji Tanaka, Toshio Matsumoto and Masahiro Abe :
The Roles of ROS Generation in RANKL-Induced Osteoclastogenesis: Suppressive Effects of Febuxostat.,
Cancers, Vol.12, No.4, 2020.
(Tokushima University Institutional Repository: 115041,   DOI: 10.3390/cancers12040929,   PubMed: 32283857)
15. Kengo Udaka, Shingen Nakamura, Shiroh Fujii, Ryosuke Miyamoto, Naoko Matsui, Shiyori Kawata, Taiki Hori, Junpei Murai, Ryohei Sumitani, Masahiro Oura, Kimiko Sogabe, Mamiko Takahashi, Takeshi Harada, Kumiko Kagawa, Yuishin Izumi, Masahiro Abe and Hirokazu Miki :
Successful treatment of progressive multifocal leukoencephalopathy with mirtazapine and mefloquine in refractory myeloma,
International Journal of Myeloma, Vol.10, No.1, 8-12, 2020.
16. Shuji Ozaki, Takeshi Harada, Hikaru Yagi, Etsuko Sekimoto, Hironobu Shibata, Toshio Shigekiyo, Shiroh Fujii, Shingen Nakamura, Hirokazu Miki, Kumiko Kagawa and Masahiro Abe :
Polyclonal Immunoglobulin Recovery after Autologous Stem Cell Transplantation Is an Independent Prognostic Factor for Survival Outcome in Patients with Multiple Myeloma,
Cancers, Vol.12, No.1, 12, 2019.
(Tokushima University Institutional Repository: 115047,   DOI: 10.3390/cancers12010012,   PubMed: 31861479,   Elsevier: Scopus)
17. 井上 雄介, Akishige Ikegame, 徳永 尚樹, 千尋 井上, Takayuki Nakao, Kojiro Nagai, 高橋 真美子, Shiroh Fujii, Shingen Nakamura and Masahiro Abe :
芽球様の形態を示した肝脾型T細胞リンパ腫の一症例,
日本検査血液学会雑誌, Vol.20, No.2, 231-237, 2019.
18. Masami Iwasa, Takeshi Harada, Asuka Oda, Ariunzaya Bat-Erdene, Jumpei Teramachi, Hirofumi Tenshin, Mohannad Ashtar, Masahiro Oura, Kimiko Sogabe, Kengo Udaka, Shiroh Fujii, Shingen Nakamura, Hirokazu Miki, Kumiko Kagawa, Shuji Ozaki and Masahiro Abe :
PD-L1 upregulation in myeloma cells by panobinostat in combination with interferon-γ.,
Oncotarget, Vol.10, No.20, 1903-1917, 2019.
(Tokushima University Institutional Repository: 113359,   DOI: 10.18632/oncotarget.26726,   PubMed: 30956773,   Elsevier: Scopus)
19. Yuko Miyakami, Shingen Nakamura, Masahiro Oura, Yasunobu Okamoto, 高橋 真美子, Kimiko Sogabe, 岩佐 昌美, Takeshi Harada, Shiroh Fujii, Hirokazu Miki, Kumiko Kagawa, Hisanori Uehara and Masahiro Abe :
De novo CD 20-negative diffuse large B-cell lymphoma developed with sustained fever and markedly high C-reactive protein level,
Shikoku Acta Medica, Vol.74, No.5-6, 193-200, 2018.
(Tokushima University Institutional Repository: 112987,   CiNii: 1050845763422780928)
20. Ariunzaya Bat-Erdene, Shingen Nakamura, Asuka Oda, Masami Iwasa, Jumpei Teramachi, Mohannad Ashtar, Takeshi Harada, Hirokazu Miki, Hirofumi Tenshin, Masahiro Hiasa, Shiroh Fujii, Kimiko Sogabe, Masahiro Oura, Kengo Udaka, Kumiko Kagawa, Sumiko Yoshida, Ken-ichi Aihara, Kiyoe Kurahashi, Itsuro Endo and Masahiro Abe :
Class 1 HDAC and HDAC6 inhibition inversely regulates CD38 induction in myeloma cells via interferon-α and ATRA.,
British Journal of Haematology, 2018.
(Tokushima University Institutional Repository: 113393,   DOI: 10.1111/bjh.15673,   PubMed: 30474853,   Elsevier: Scopus)
21. Jumpei Teramachi, Masahiro Hiasa, Asuka Oda, Takeshi Harada, Shingen Nakamura, Ryota Amachi, Hirofumi Tenshin, Masami Iwasa, Shiroh Fujii, Kumiko Kagawa, Hirokazu Miki, Kiyoe Kurahashi, Sumiko Yoshida, Itsuro Endo, Tatsuji Haneji, Toshio Matsumoto and Masahiro Abe :
Pim-2 is a critical target for treatment of osteoclastogenesis enhanced in myeloma.,
British Journal of Haematology, Vol.180, No.4, 581-585, 2018.
(Tokushima University Institutional Repository: 112935,   DOI: 10.1111/bjh.14388,   PubMed: 27748523)
22. Shiroh Fujii, Shingen Nakamura, Asuka Oda, Hirokazu Miki, Hirofumi Tenshin, Jumpei Teramachi, Masahiro Hiasa, Ariunzaya Bat-Erdene, Yusaku Maeda, Masahiro Oura, Mamiko Takahashi, Masami Iwasa, Itsuro Endo, Sumiko Yoshida, Ken-ichi Aihara, Kiyoe Kurahashi, Takeshi Harada, Kumiko Kagawa, Michiyasu Nakao, Shigeki Sano and Masahiro Abe :
Unique anti-myeloma activity by thiazolidine-2,4-dione compounds with Pim inhibiting activity.,
British Journal of Haematology, Vol.180, No.2, 246-258, 2018.
(Tokushima University Institutional Repository: 112752,   DOI: 10.1111/bjh.15033,   PubMed: 29327347,   Elsevier: Scopus)
23. 山口 純代, Shingen Nakamura, 住田 智志, 前田 悠作, Masahiro Oura, 高橋 真美子, 岩佐 昌美, Takeshi Harada, Shiroh Fujii, Hirokazu Miki, Kumiko Kagawa, Jun Kishi and Masahiro Abe :
Development of adult T-cell leukemia/lymphoma during immunosuppressive Therapy for human T-cell leukemia virus type 1 associated arthropathy,
Shikoku Acta Medica, Vol.73, No.5,6, 301-308, 2017.
(Tokushima University Institutional Repository: 112059,   CiNii: 1050001338847982080)
24. Hirokazu Miki, Shingen Nakamura, Asuka Oda, Hirofumi Tenshin, Jumpei Teramachi, Masahiro Hiasa, Ariunzaya Bat-Erdene, Yusaku Maeda, Masahiro Oura, Mamiko Takahashi, Masami Iwasa, Takeshi Harada, Shiroh Fujii, Kiyoe Kurahashi, Sumiko Yoshida, Kumiko Kagawa, Itsuro Endo, Aihara Kenichi, Mariko Ikuo, Kouji Itou, Koichiro Hayashi, Michihiro Nakamura and Masahiro Abe :
Effective impairment of myeloma cells and their progenitors by hyperthermia.,
Oncotarget, Vol.9, No.12, 10307-10316, 2017.
(Tokushima University Institutional Repository: 113059,   DOI: 10.18632/oncotarget.23121,   PubMed: 29535808,   Elsevier: Scopus)
25. Hirofumi Tenshin, Jumpei Teramachi, Asuka Oda, Ryota Amachi, Masahiro Hiasa, Ariunzaya Bat-Erdene, Keiichiro Watanabe, Masami Iwasa, Takeshi Harada, Shiroh Fujii, Kumiko Kagawa, Kimiko Sogabe, Shingen Nakamura, Hirokazu Miki, Kiyoe Kurahashi, Sumiko Yoshida, Kenichi Aihara, Itsuro Endo, Eiji Tanaka, Toshio Matsumoto and Masahiro Abe :
TAK1 inhibition subverts the osteoclastogenic action of TRAIL while potentiating its antimyeloma effects.,
Blood Advances, Vol.1, No.24, 2124-2137, 2017.
(Tokushima University Institutional Repository: 111724,   DOI: 10.1182/bloodadvances.2017008813,   PubMed: 29296860)
26. Ariunzaya Bat-Erdene, Hirokazu Miki, Asuko Oda, Shingen Nakamura, Jumpei Teramachi, Ryota Amachi, Hirofumi Tenshin, Masahiro Hiasa, Masami Iwasa, Takeshi Harada, Shiroh Fujii, Kimiko Sogabe, Kumiko Kagawa, Sumiko Yoshida, Itsuro Endo, Ken-ichi Aihara and Masahiro Abe :
Synergistic targeting of Sp1, a critical transcription factor for myeloma cell growth and survival, by panobinostat and proteasome inhibitors.,
Oncotarget, Vol.7, No.48, 79064-79075, 2016.
(Tokushima University Institutional Repository: 109988,   DOI: 10.18632/oncotarget.12594,   PubMed: 27738323)
27. Ryota Amachi, Masahiro Hiasa, Jumpei Teramachi, Takeshi Harada, Asuka Oda, Shingen Nakamura, Derek Hanson, Keiichiro Watanabe, Shiroh Fujii, Hirokazu Miki, Kumiko Kagawa, Masami Iwasa, Itsuro Endo, Takeshi Kondo, Sumiko Yoshida, Ken-ichi Aihara, Kiyoe Kurahashi, Yoshiaki Kuroda, Hideaki Horikawa, Eiji Tanaka, Masahiro Abe and Toshio Matsumoto :
A vicious cycle between acid sensing and survival signaling in myeloma cells: acid-induced epigenetic alteration.,
Oncotarget, Vol.7, No.43, 70447-70461, 2016.
(Tokushima University Institutional Repository: 113048,   DOI: 10.18632/oncotarget.11927,   PubMed: 27626482)
28. Takeshi Harada, Hirokazu Miki, Q Cui, A Oda, Ryota Amachi, Jumpei Teramachi, A Bat-Erdene, K Sogabe, M Iwasa, Shiroh Fujii, Shingen Nakamura, Kumiko Kagawa, Sumiko Yoshida, I Endo, Ken-ichi Aihara, Shuji Ozaki, Toshio Matsumoto and Masahiro Abe :
Expansion of Th1-like V9V2T cells by new-generation IMiDs, lenalidomide and pomalidomide, in combination with zoledronic acid.,
Leukemia, Vol.31, No.1, 258-262, 2016.
(DOI: 10.1038/leu.2016.273,   PubMed: 27698446)
29. Michiko Yamashita, Yoshiyuki Fujii, Keiji Ozaki, Yoshio Urano, Masami Iwasa, Shingen Nakamura, Shiroh Fujii, Masahiro Abe, Yasuharu Sato and Tadashi Yoshino :
Human immunodeficiency virus-positive secondary syphilis mimicking cutaneous T-cell lymphoma.,
Diagnostic Pathology, Vol.10, 185, 2015.
(DOI: 10.1186/s13000-015-0419-5,   PubMed: 26449225,   Elsevier: Scopus)
30. Shingen Nakamura, Hirokazu Miki, Asuka Oda, Ryota Amachi, Jumpei Teramachi, Kimiko Sogabe, Hikaru Fujino, Tomoko Maruhashi, Shiroh Fujii, Kumiko Kagawa and Masahiro Abe :
Susceptibility to bendamustine considerably varies among myeloma cells, but is enhanced in acidic conditions,
International Journal of Myeloma, Vol.6, No.1, 7-11, 2015.
31. Hirokazu Miki, Shingen Nakamura, A Oda, R Amachi, Keiichiro Watanabe, D Hanson, Jumpei Teramachi, Masahiro Hiasa, H Yagi, K Sogabe, M Takahashi, T Maruhashi, K Udaka, T Harada, Shiroh Fujii, A Nakano, Kumiko Kagawa, M Ri, S Iida, Shuji Ozaki, T Matsumoto and Masahiro Abe :
Induction of endoplasmic reticulum stress by bortezomib sensitizes myeloma cells to DR5-mediated cell death,
International Journal of Myeloma, Vol.5, No.1, 1-7, 2015.
(DOI: 10.57352/ijm.5.1_1,   CiNii: 1390292815284471040)
32. Kumiko Kagawa, Shingen Nakamura, 八木 ひかる, Kimiko Sogabe, 髙橋 真美子, 丸橋 朋子, 宇髙 憲吾, Shiroh Fujii, Hirokazu Miki and Masahiro Abe :
Successful treatment of refractory severe aplastic anemia with bone marrow transplantation from a genetically identical twin,
Shikoku Acta Medica, Vol.70, No.3,4, 77-80, 2014.
(Tokushima University Institutional Repository: 109757,   CiNii: 1050001337464993408)
33. Masahiro Hiasa, Jumpei Teramachi, A Oda, Ryota Amachi, T Harada, Shingen Nakamura, Hirokazu Miki, Shiroh Fujii, Kumiko Kagawa, Keiichiro Watanabe, Itsuro Endo, Y Kuroda, T Yoneda, Daisuke Tsuji, Michiyasu Nakao, Eiji Tanaka, Kenichi Hamada, Shigeki Sano, Kouji Itou, Toshio Matsumoto and Masahiro Abe :
Pim-2 kinase is an important target of treatment for tumor progression and bone loss in myeloma.,
Leukemia, 2014.
(DOI: 10.1038/leu.2014.147,   PubMed: 24787487)
34. Takeshi Harada, Shuji Ozaki, Asuka Oda, Daisuke Tsuji, Akishige Ikegame, Masami Iwasa, Kengo Udaka, Shiroh Fujii, Shingen Nakamura, Hirokazu Miki, Kumiko Kagawa, Yoshiaki Kuroda, Shigeto Kawai, Kouji Itou, Hisafumi Yamada-Okabe, Toshio Matsumoto and Masahiro Abe :
Combination with a Defucosylated Anti-HM1.24 Monoclonal Antibody plus Lenalidomide Induces Marked ADCC against Myeloma Cells and Their Progenitors,
PLoS ONE, Vol.8, No.12, e83905, 2013.
(Tokushima University Institutional Repository: 106068,   DOI: 10.1371/journal.pone.0083905,   PubMed: 24386306,   Elsevier: Scopus)
35. Shingen Nakamura, Hirokazu Miki, Shinsuke Kido, Ayako Nakano, Masahiro Hiasa, Asuka Oda, Hiroe Amou, Keiichiro Watanabe, Takeshi Harada, Shiroh Fujii, Kyoko Takeuchi, Kumiko Kagawa, Shuji Ozaki, Toshio Matsumoto and Masahiro Abe :
Activating transcription factor 4, an ER stress mediator, is required for, but exce ssive ER stress suppresses osteoblastogenesis by bortezomib.,
International Journal of Hematology, Vol.98, No.1, 66-73, 2013.
(Tokushima University Institutional Repository: 105938,   DOI: 10.1007/s12185-013-1367-z,   PubMed: 23708974,   Elsevier: Scopus)
36. Keisuke Fujioka, Atsuro Saijo, Yuko Toyoda, Souji Kakiuchi, Masaki Hanibuchi, Masahiko Azuma, Kyoko Takeuchi, Shiroh Fujii, Shingen Nakamura, Kengo Utaka, Kumiko Kagawa, Masahiro Abe, Tomoya Mizutani and Yasuhiko Nishioka :
皮膚ランダム生検が診断に有用であった血管内リンパ腫の一例,
Shikoku Acta Medica, Vol.67, No.5,6, 257-262, 2011.
(Tokushima University Institutional Repository: 97858,   CiNii: 1050001337463886208)
37. Hirokazu Miki, Shingen Nakamura, Shuji Ozaki, A Oda, H Amou, Akishige Ikegame, Keiichiro Watanabe, Masahiro Hiasa, Q Cui, T Harada, Shiroh Fujii, A Nakano, Kumiko Kagawa, Kyoko Takeuchi, Ken-ichiro Yata, A Sakai, Masahiro Abe and Toshio Matsumoto :
KRN5500, a spicamycin derivative, exerts anti-myeloma effects through impairing both myeloma cells and osteoclasts.,
British Journal of Haematology, Vol.155, No.3, 328-339, 2011.
(DOI: 10.1111/j.1365-2141.2011.08844.x,   PubMed: 21902681)
38. Qu Cui, Hironobu Shibata, Asuka Oda, Hiroe Amou, Ayako Nakano, Kenichiro Yata, Masahiro Hiasa, Keiichiro Watanabe, Shingen Nakamura, Hirokazu Miki, Takeshi Harada, Shiroh Fujii, Kumiko Kagawa, Kyoko Takeuchi, Shuji Ozaki, Toshio Matsumoto and Masahiro Abe :
Targeting myeloma-osteoclast interaction with V9V2 T cells.,
International Journal of Hematology, Vol.94, No.1, 63-70, 2011.
(DOI: 10.1007/s12185-011-0885-9,   PubMed: 21698356)
39. J Asano, A Nakano, A Oda, H Amou, Masahiro Hiasa, Kyoko Takeuchi, H Miki, S Nakamura, T Harada, Shiroh Fujii, Kumiko Kagawa, Itsuro Endo, Ken-ichiro Yata, A Sakai, Shuji Ozaki, Toshio Matsumoto and Masahiro Abe :
The serine/threonine kinase Pim-2 is a novel anti-apoptotic mediator in myeloma cells.,
Leukemia, 2011.
(Tokushima University Institutional Repository: 106134,   DOI: 10.1038/leu.2011.60,   PubMed: 21475253)

Proceeding of International Conference:

1. Takeshi Harada, Asuka Oda, Yosuke Matsushita, Ryohei Sumitani, Yusuke Inoue, Tomoyo Hara, Masahiro Oura, Kimiko Sogabe, Tomoko Maruhashi, Mamiko Takahashi, Kiyoe Kurahashi, Shiroh Fujii, Shingen Nakamura, Hirokazu Miki, Masahiro Hiasa, Jumpei Teramachi, Toyomasa Katagiri and Masahiro Abe :
ADAR1-dsRNA metabolism in myeloma cells with 1q amplification: a novel therapeutic target,
19th International Myeloma Society Annual Meeting, Aug. 2022.
2. Takeshi Harada, Yusuke Inoue, Hirofumi Tenshin, Asuka Oda, Ryohei Sumitani, Masahiro Oura, Kimiko Sogabe, Shiroh Fujii, Shingen Nakamura, Hirokazu Miki, Masahiro Hiasa, Jumpei Teramachi and Masahiro Abe :
Novel strategy of elotuzumab and zoledronic acid with Th1-like T cells against myeloma,
18th International Myeloma Workshop, Wien, Sep. 2021.
3. Takeshi Harada, Yusuke Inoue, Hirofumi Tenshin, Asuka Oda, Ryohei Sumitani, Masahiro Oura, Kimiko Sogabe, Shiroh Fujii, Shingen Nakamura, Hirokazu Miki, Kumiko Kagawa, Masahiro Hiasa, Jumpei Teramachi and Masahiro Abe :
Induction of elotuzumabs ADCC activity by Th1-like T cells towards osteoclasts as well as myeloma cells,
EHA2021 Virtual Congress, Jun. 2021.
4. Takeshi Harada, Asuka Oda, Hiroto Ohguchi, Yohann Grondin, Hirofumi Tenshin, Masahiro Hiasa, Jumpei Teramachi, Masahiro Oura, Kimiko Sogabe, Shiroh Fujii, Shingen Nakamura, Hirokazu Miki, Hirokazu Miki, Kumiko Kagawa, Shuji Ozaki, Teru Hideshima, Kenneth C. Anderson and Masahiro Abe :
Novel therapeutic rationale for targeting HDAC1 and PIM2 in multiple myeloma,
61th ASH Annual Meeting & Exposition, Orlando, Dec. 2019.
(DOI: 10.1182/blood-2019-127679)
5. Takeshi Harada, Asuka Oda, Hirofumi Tenshin, Jumpei Teramachi, Masahiro Oura, Kimiko Sogabe, Shiroh Fujii, Shingen Nakamura, Hirokazu Miki, Kumiko Kagawa, Shuji Ozaki, Teru Hideshima, C. Kenneth Anderson and Masahiro Abe :
Targeting myeloma metabolisms regulated by HDAC1-IRF4 axis can be a novel therapeutic strategy,
17th International Myeloma Workshop, Sep. 2019.
6. Mohannad Ashtar, Hirofumi Tenshin, Jumpei Teramachi, Masahiro Hiasa, Kotaro Tanimoto, Oda Asuka, Iwasa Masami, Takeshi Harada, Bat-Erdene Ariunzaya, Kimiko Sogabe, Masahiro Oura, Shiroh Fujii, Kumiko Kagawa, Shingen Nakamura, Hirokazu Miki, Toshio Matsumoto, Masahiro Abe and Eiji Tanaka :
Peri-implantitis and the role of Febuxostat in osteoclast differentiation.,
AEEDC Dubai World Orthodontic Conference, Dubai, UAE, Feb. 2019.
7. Takeshi Harada, Asuka Oda, Yohann Grondin, Jumpei Teramachi, Ariunzaya Bat-Erdene, Masami Iwasa, Masahiro Oura, Shingen Nakamura, Kumiko Kagawa, Yasunobu Okamoto, Kimiko Sogabe, Shiroh Fujii, Hirokazu Miki, Shuji Ozaki, Teru Hideshima, Kenneth C. Anderson and Masahiro Abe :
The critical role of the HDAC1-IRF4-Pim-2 axis in myeloma cell growth and survival: therapeutic impacts of targeting the HDAC1-IRF4-Pim-2 axis,
60th ASH Annual Meeting & Exposition, San Diego, Dec. 2018.
8. Shingen Nakamura, Hirokazu Miki, Ariunzaya Bat-Erdene, Yasunobu Okamoto, Kimiko Sogabe, Masahiro Oura, Mamiko Takahashi, Masami Iwasa, Takeshi Harada, Shiroh Fujii, Kumiko Kagawa and Masahiro Abe :
Alteration of muscle mass after chemotherapy in patients with newly diagnosed multiple myeloma.,
Esmo asia 2018, Nov. 2018.
9. Takeshi Harada, Oda Asuka, Jumpei Teramachi, Bat-Erdene Ariunzaya, Iwasa Masami, Oura Masahiro, Shingen Nakamura, Kumiko Kagawa, Okamoto Yasunobu, Kimiko Sogabe, Shiroh Fujii, Hirokazu Miki, Hideshima Teru, Anderson C. Kenneth and Masahiro Abe :
Selective inhibition of class-I HDAC induces myeloma cell death through targeting IRF4-Pim-2 axis,
The 9th JSH International Symposium 2018 in Kyoto, Jul. 2018.
10. Ryota Amachi, Masahiro Hiasa, Oda Asuka, Bat-Erdene Ariunzaya, Jumpei Teramachi, Hirofumi Tenshin, Keiichiro Watanabe, Shingen Nakamura, Hirokazu Miki, Kumiko Kagawa, Shiroh Fujii, Toshio Matsumoto, Eiji Tanaka and Masahiro Abe :
Osteoblast Creates a Non-permissive Niche for Myeloma Cells,
95th General Session & Exhibition of the IADR program book, San Francisco, Mar. 2017.
11. Jumpei Teramachi, Masahiro Hiasa, Asuka Oda, Hirofumi Tenshin, Ryota Amachi, Takeshi Harada, Derek Hanson, Keiichiro Watanabe, Shiroh Fujii, Kumiko Kagawa, Shingen Nakamura, Hirokazu Miki, Itsuro Endo, Shuji Ozaki, Toshio Matsumoto and Masahiro Abe :
Pim inhibition suppresses osteoclastogenesis and tumor growth in myeloma,
57th ASH Annual Meeting and Exposition, Orlando, Dec. 2015.
12. Ryota Amachi, Masahiro Hiasa, Jumpei Teramachi, Asuka Oda, Hirofumi Tenshin, Keiichiro Watanabe, Shingen Nakamura, Hirokazu Miki, Kumiko Kagawa, Shiroh Fujii, Itsuro Endo, Eiji Tanaka, Toshio Matsumoto and Masahiro Abe :
Up-regulation of the pH sensor TRPV1 in myeloma cells and their adaption to an acidic microenvironment,
ASBMR 2015 Annual Meeting, Seattle, Oct. 2015.
13. Jumpei Teramachi, Masahiro Hiasa, Asuka Oda, Hirofumi Tenshin, Ryota Amachi, Takeshi Harada, Keiichiro Watanabe, Shiroh Fujii, Kumiko Kagawa, Shingen Nakamura, Hirokazu Miki, Itsuro Endo, Tatsuji Haneji, Toshio Matsumoto and Masahiro Abe :
Pivotal role of TAK-1 in tumor growth and bone destruction in myeloma: Therapeutic impact of TAK-1 inhibition,
American Society for Bone and Mineral Research 2015 Annual Meeting, Oct. 2015.
14. Hirokazu Miki, Shingen Nakamura, Hirofumi Tenshin, Ryota Amachi, Keiichiro Watanabe, Jumpei Teramachi, Shiroh Fujii, Kumiko Kagawa and Masahiro Abe :
Effective impairment of myeloma progenitors by hyperthermia: augmentation with bortezomib and Pim inhibition in combination,
Clinical Lymphoma, Myeloma & Leukemia, Vol.15, No.S3, e217-e218, Sep. 2015.
(DOI: 10.1016/j.clml.2015.07.470)
15. Shingen Nakamura, Hirokazu Miki, Hirofumi Tenshin, Ryota Amachi, Keiichiro Watanabe, Jumpei Teramachi, Shiroh Fujii, Kumiko Kagawa and Masahiro Abe :
Alteration of Pim-2 expression by clinically available anti-myeloma agents: combinatory anti-myeloma effects with Pim inhibition,
Clinical Lymphoma, Myeloma & Leukemia, Vol.15, No.S3, e243, Sep. 2015.
(DOI: 10.1016/j.clml.2015.07.517)
16. Jumpei Teramachi, Masahiro Hiasa, 小田 明日香, Ryota Amachi, Takeshi Harada, Shingen Nakamura, Kumiko Kagawa, Hirokazu Miki, Shiroh Fujii, Keiichiro Watanabe, Itsuro Endo, Toshio Matsumoto and Masahiro Abe :
Critical role of Pim-2 in NF-B-mediated suppression of osteoblastogenesis and stimulation of osteoclastogenesis: Therapeutic impact of Pim inhibition on myeloma bone disease.,
2014 ASBMR Annual Meeting, Houston, Sep. 2014.
17. Keiichiro Watanabe, Masahiro Abe, Ryota Amachi, Masahiro Hiasa, T Harada, Shiroh Fujii, Shingen Nakamura, Hirokazu Miki, Kumiko Kagawa, H Mori, Itsuro Endo, Eiji Tanaka and Toshio Matsumoto :
Induction of bone formation in myeloma osteolytic lesions by cathepsinK inhibition,
Kyoto, Apr. 2013.
18. Ryota Amachi, Keiichiro Watanabe, Shiroh Fujii, T Harada, Hirokazu Miki, Shingen Nakamura, A Oda, Masahiro Hiasa, Eiji Tanaka, Toshio Matsumoto and Masahiro Abe :
An acidic milieu suppersses histone acetylation in myeloma cells to down-regulate the TRAIL receptor DR4 expression.,
Kyoto, Apr. 2013.
19. Harada Takeshi, Ozaki Shuji, Oda Asuka, Iwasa Masami, Shiroh Fujii, Shingen Nakamura, Hirokazu Miki, Kumiko Kagawa, Masahiro Abe, Shibata Hironobu, Akishige Ikegame, Daisuke Tsuji, Ito Kohji, Ri Masaki, Iida Shinsuke, Shiotsu Yukimasa, Kawai Shigeto, Yamada-Okabe Hisafumi and Toshio Matsumoto :
Combination therapy of a defucosylated anti-HM1.24 monoclonal antibody plus Ienalidomide induces marked antibody-dependent cellular cytotoxicity and inhibits the clonogenic potential of myeloma cancer stem-like cells. Atlanta, Dec. 2012.,
The 54th Annual Meeting of the American Society of Hamatology, Dec. 2012.
20. T Harada, Shuji Ozaki, A Oda, M Iwasa, Shiroh Fujii, Shingen Nakamura, Hirokazu Miki, Kumiko Kagawa, Masahiro Abe, Hirofumi Shibata, Akishige Ikegame, Daisuke Tsuji, Kouji Itou, M Ri, S Iida, Y Shiotsu, S Kawai, H Yamada-Okabe and Toshio Matsumoto :
Combination Therapy of a Defucosylated Anti-HM1.24 Monoclonal Antibody Plus Lenalidomide Induces Marked Antibody-Dependent Cellular Cytotoxicity and Inhibits the Clonogenic Potential of Myeloma Cancer Stem-Like Cells.,
54th ASH Annual Meeting and Exposition, USA, Atlanta, Dec. 2012.
21. Keiichiro Watanabe, Masahiro Abe, M Kawatani, Masahiro Hiasa, A Kawano, T Jinno, T Harada, Shiroh Fujii, Shingen Nakamura, Hirokazu Miki, Kumiko Kagawa, Kyoko Takeuchi, Shuji Ozaki, Eiji Tanaka, H Osada and Toshio Matsumoto :
Aggravation of myeloma growth and drug resistance by an acidic created in myeloma-osteoclast interaction.,
ASBMR 2011 Annual Meeting, San Diego, Sep. 2011.
22. Masahiro Hiasa, nakano ayako, Keiichiro Watanabe, C Qu, T Harada, Shiroh Fujii, Hirokazu Miki, Shingen Nakamura, Kumiko Kagawa, Kyoko Takeuchi, Eiji Tanaka, Kenzo Asaoka, Shuji Ozaki, Toshio Matsumoto and Masahiro Abe :
Prevention of tumor growth and bone destruction in myeloma by Pim kinase inhibition.,
ASBMR 2011 Annual Meeting, San Diego, Sep. 2011.
23. Masahiro Hiasa, nakano ayako, Keiichiro Watanabe, C Qu, T Harada, Shiroh Fujii, Hirokazu Miki, Shingen Nakamura, Kumiko Kagawa, Kyoko Takeuchi, Eiji Tanaka, Kenzo Asaoka, Shuji Ozaki, Toshio Matsumoto and Masahiro Abe :
Dual effects of Pim inhibition on myeloma: induction of bone formation and tumor suppression.,
IOF-ANZBMS 2011 Annual Meeting, Gold Coast, Sep. 2011.
24. Keiichiro Watanabe, Masahiro Abe, Cui Qu, Kawatani Makoto, Masahiro Hiasa, Nakano Ayako, Jinno Tadashi, Harada Takeshi, Shiroh Fujii, Shingen Nakamura, Miki Hirokazu, Kumiko Kagawa, Kyoko Takeuchi, Shuji Ozaki, Eiji Tanaka, Osada Hiroyuki and Toshio Matsumoto :
An Acidic Mileu Created In Myeloma-Osteoclast Interaction Enhances Tumor Growth, but Triggers Anti-Myeloma Activity of Reveromycin A, a Novel Anti-Resorptive Agent,
52th American Society of Hematology, Orlando, Dec. 2010.
25. Cui Qu, Masahiro Abe, Miki Hirokazu, Shingen Nakamura, Keiichiro Watanabe, Akishige Ikegame, Masahiro Hiasa, Nakano Ayako, Harada Takeshi, Shiroh Fujii, Kumiko Kagawa, Kyoko Takeuchi, Shuji Ozaki and Toshio Matsumoto :
Lenalidomide In Combination with Zoledronic Acid Restores the Activation and Anti-Myeloma Effects of γδT Cells Attenuated by the Bone Marrow Microenvironment,
52th American Society of Hematology, Orlando, Dec. 2010.
26. Keiichiro Watanabe, Masahiro Abe, Cui Qu, Kawatani Makoto, Masahiro Hiasa, Nakano Ayako, Jinno Tadashi, Harada Takeshi, Shiroh Fujii, Shingen Nakamura, Miki Hirokazu, Kumiko Kagawa, Kyoko Takeuchi, Shuji Ozaki, Eiji Tanaka, Osada Hiroyuki and Toshio Matsumoto :
A Novel Anti-resorptive Agent, Reveromycin A, Ameliorates Bone Destruction and Tumor Growth in Myeloma,
ASBMR 2010 Annual Meeting, Toronto, Oct. 2010.
27. Keiichiro Watanabe, Masahiro Abe, Cui Qu, Kawatani Makoto, Masahiro Hiasa, Nakano Ayako, Jinno Tadashi, Harada Takeshi, Shiroh Fujii, Shingen Nakamura, Miki Hirokazu, Kumiko Kagawa, Kyoko Takeuchi, Shuji Ozaki, Eiji Tanaka, Osada Hiroyuki and Toshio Matsumoto :
The novel anti-resorptive agent reveromycin A ameliorates bone destruction and tumor growth in myeloma,
10th International Conference Cancer-induced Bone Disease, Sheffield (United Kingdom), Sep. 2010.

Proceeding of Domestic Conference:

1. 明石 和子, Yoshie Imai, Shingen Nakamura, 西條 早希, 前田 悠作, Ryohei Sumitani, Masahiro Oura, Kimiko Sogabe, 髙橋 真美子, Takeshi Harada, Shiroh Fujii and Hirokazu Miki :
初回再発した成人期の造血器腫瘍患者が捉える化学療法への構え,
第21回日本臨床腫瘍学会学術集, Feb. 2024.
2. 明石 和子, Yoshie Imai, Shingen Nakamura, 西條 早希, 前田 悠作, Ryohei Sumitani, Masahiro Oura, Kimiko Sogabe, 髙橋 真美子, Takeshi Harada, Shiroh Fujii and Hirokazu Miki :
初回再発した成人期の造血器腫瘍患者が捉える化学療法への構え,
第21回日本臨床腫瘍学会学術集, Feb. 2024.
3. 明石 和子, Yoshie Imai, Shingen Nakamura, 西條 早希, 前田 悠作, Ryohei Sumitani, Masahiro Oura, Kimiko Sogabe, 髙橋 真美子, Takeshi Harada, Shiroh Fujii and Hirokazu Miki :
再発・難治性造血器腫瘍患者が捉えるアドバンス・ケア・プランニング,
第61回日本癌治療学会学術集会, Oct. 2023.
4. Ryohei Sumitani, Shingen Nakamura, Masahiro Oura, Kimiko Sogabe, 髙橋 真美子, Shiroh Fujii, Takeshi Harada, Hirokazu Miki and Masahiro Abe :
周期的な発熱,血小板減少,高LDH血症で発症したびまん性大細胞型B細胞リンパ腫の1例,
第128回日本内科学会四国地方会, Jul. 2023.
5. 佃 恵里加, 李 悦子, 瀧本 朋美, 小田 直輝, Takeshi Harada, Shiroh Fujii, Shingen Nakamura, Hirokazu Miki and Masahiro Abe :
ダラツムマブ投与患者における間接抗グロブリン試験干渉期間の検討,
Japanese Journal of Transfusion and Cell Therapy, Vol.68, No.6, 582-583, Dec. 2022.
6. Mamiko Takahashi, Shingen Nakamura, Shin Kondo, Masafuumi Nakamura, Ryohei Sumitani, Masahiro Oura, Kimiko Sogabe, Takeshi Harada, Shiroh Fujii, Hirokazu Miki and Masahiro Abe :
Importance of skeletal muscle mass during chemotherapies in patients with hematological malignancies,
JSH2022, Oct. 2022.
7. Takeshi Harada, Ryohei Sumitani, Asuka Oda, Yusuke Inoue, Masahiro Oura, Kimiko Sogabe, Tomoko Maruhashi, Mamiko Takahashi, Shiroh Fujii, Shingen Nakamura, Hirokazu Miki, Kumiko Kagawa, Shuji Ozaki, Hirofumi Tenshin, Masahiro Hiasa, Jumpei Teramachi and Masahiro Abe :
The therapeutic potential targeting ADAR1-dsRNA metabolism in myeloma cells with 1q amplification,
The 84th Annual Meeting of the Japanese Society of Hematology, Oct. 2022.
8. 新居 寛子, 髙橋 真美子, Shiroh Fujii, Kimiko Sogabe, 林 成樹, Ryohei Sumitani, Masahiro Oura, Takeshi Harada, Shingen Nakamura, 安積 麻衣, 湊 将典, Hirokazu Miki and Masahiro Abe :
ループス腎炎に対してミコフェノール酸モフェチル投与中に発症した他の医原性免疫不全関連リンパ増殖性疾患の1例,
第265回徳島医学会学術集会, Jul. 2022.
9. Ryohei Sumitani, Makiko Mizuguchi, Masahiro Oura, Shiroh Fujii, Shingen Nakamura, Hirokazu Miki, Kumiko Kagawa, Toshihiro Hashimoto, Takeshi Harada and Masahiro Abe :
126,
第126回日本内科学会四国地方会, Jun. 2022.
10. 中村 昌史, Hirokazu Miki, Ryohei Sumitani, Masahiro Oura, Kimiko Sogabe, 丸橋 朋子, 高橋 真美子, Takeshi Harada, Shiroh Fujii, Shingen Nakamura, 西尾 進, Tetsu Tomonari and Masahiro Abe :
ALアミロイドーシスの肝病変の評価における超音波エラストグラフィの有用性,
The Japanese Journal of Clinical Hematology, Vol.63, No.6, 685-686, Jun. 2022.
11. Shingen Nakamura, HORI Taiki, Masafumi Nakamura, Ryohei Sumitani, Masahiro Oura, Kimiko Sogabe, Tomoko Maruhashi, 高橋 真美子, Shiroh Fujii, Hirokazu Miki, Takeshi Harada and Masahiro Abe :
Humoral response of the mRNA vaccine against SARS-CoV-2 in patients with plasma cell dyscrasia,
The 47th annual meeting of Japanese Society of Myeloma, May 2022.
12. Hirofumi Tenshin, Takeshi Harada, 井上 雄介, 菊池 次郎, 小田 明日香, Ryohei Sumitani, Masahiro Oura, Kimiko Sogabe, 丸橋 朋子, 高橋 真美子, Shiroh Fujii, Shingen Nakamura, Hirokazu Miki, Masahiro Hiasa, Jumpei Teramachi, 鈴木 敦, 角川 学士, 峯畑 健一, 古川 雄祐 and Masahiro Abe :
Osteoclasts robustly express SLAMF7 and secrete soluble SLAMF7,
The 47th Annual Meeting of the Japanese Society of Myeloma, May 2022.
13. 井上 雄介, Takeshi Harada, Hirofumi Tenshin, 小田 明日香, Ryohei Sumitani, Masahiro Oura, Kimiko Sogabe, 丸橋 朋子, 高橋 真美子, Shiroh Fujii, Hirokazu Miki, Shingen Nakamura, Masahiro Hiasa, Jumpei Teramachi and Masahiro Abe :
Leverage of Th1-like γδT cells into antibody-mediated immunotherapy against myeloma,
The 47th Annual Meeting of the Japanese Society of Myeloma, May 2022.
14. Takeshi Harada, Ryohei Sumitani, Asuka Oda, Inoue Yusuke, Masahiro Oura, Kimiko Sogabe, Tomoko Maruhashi, Takahashi Mamiko, Shiroh Fujii, Shingen Nakamura, Hirokazu Miki, Hirofumi Tenshin, Masahiro Hiasa, Jumpei Teramachi and Masahiro Abe :
Therapeutic impact of targeting RNA editing enzyme ADAR1 on myeloma cells with 1q amplification,
第47回日本骨髄腫学会学術集会, May 2022.
15. Jumpei Teramachi, Hirofumi Tenshin, Masahiro Hiasa, 小田 明日香, Sou Shimizu, Ryohei Sumitani, Masahiro Oura, Kimiko Sogabe, 丸橋 朋子, Shiroh Fujii, Shingen Nakamura, Hirokazu Miki, Itsuro Endo, Takeshi Harada and Masahiro Abe :
TAK1 阻害は骨髄腫の細胞間相互作用による骨破壊と薬剤耐性を改善する,
第47回日本骨髄腫学会学術集会, May 2022.
16. 丸橋 朋子, Hirokazu Miki, Kimiko Sogabe, Takeshi Harada, 小田 明日香, Shingen Nakamura, 中村 昌史, Ryohei Sumitani, Masahiro Oura, 高橋 真美子, Shiroh Fujii and Masahiro Abe :
骨髄腫細胞のプロテアソーム阻害薬への抵抗性の機序と温熱療法によるその克服の可能性,
第47回日本骨髄腫学会学術集会, May 2022.
17. Shingen Nakamura, 堀 太貴, 中村 昌史, Ryohei Sumitani, Masahiro Oura, Kimiko Sogabe, 丸橋 朋子, 髙橋 真美子, Shiroh Fujii, Hirokazu Miki, Takeshi Harada and Masahiro Abe :
形質細胞疾患における新型コロナワクチンの有効性,
第47回日本骨髄腫学会学術集会, May 2022.
18. Hirokazu Miki, Shingen Nakamura, 中村 昌史, Ryohei Sumitani, Masahiro Oura, Kimiko Sogabe, 髙橋 真美子, 丸橋 朋子, Takeshi Harada, Shiroh Fujii, 西尾 進, 友成 哲 and Masahiro Abe :
肝臓アミロイドーシスに対する超音波エラストグラフィを用いた非侵襲的診断法の有用性,
第47回日本骨髄腫学会学術集会, May 2022.
19. Shingen Nakamura, 堀 太貴, 中村 昌史, Ryohei Sumitani, Masahiro Oura, Kimiko Sogabe, 丸橋 朋子, 高橋 真美子, Shiroh Fujii, Hirokazu Miki, Takeshi Harada, Ken-ichi Aihara and Masahiro Abe :
形質細胞異常症患者におけるSARS-CoV-2に対するmRNAワクチンの液性免疫応答の評価(Humoral response of the mRNA vaccine against SARS-CoV-2 in patients with plasma cell dyscrasia),
International Journal of Myeloma, Vol.12, No.3, 199, May 2022.
20. Hirofumi Tenshin, Takeshi Harada, 井上 雄介, 菊池 次郎, 小田 明日香, Ryohei Sumitani, Masahiro Oura, Kimiko Sogabe, 丸橋 朋子, 高橋 真美子, Shiroh Fujii, Shingen Nakamura, Hirokazu Miki, Masahiro Hiasa, Jumpei Teramachi, 鈴木 敦, 角川 学士, 峯畑 健一, 古川 雄祐 and Masahiro Abe :
破骨細胞はSLAMF7を強発現し可溶性SLAMF7を産生する(Osteoclasts robustly express SLAMF7 and secrete soluble SLAMF7),
International Journal of Myeloma, Vol.12, No.3, 150, May 2022.
21. 高原 由実子, Hirokazu Miki, Shingen Nakamura, 中村 昌史, Ryohei Sumitani, Masahiro Oura, Kimiko Sogabe, 高橋 真美子, 丸橋 朋子, Takeshi Harada, Shiroh Fujii, Masahiro Abe, 岡本 秀樹, 岡田 直人, 矢野 由美子, 高橋 真理, 青田 桂子 and Shuji Ozaki :
HIV感染症および後天性免疫不全症候群患者の臨床的特徴と今後の課題,
Shikoku Acta Medica, Vol.78, No.1-2, 89, Apr. 2022.
22. Ryohei Sumitani, Takeshi Harada, 中村 昌史, 水口 槙子, Masahiro Oura, Kimiko Sogabe, 丸橋 朋子, 髙橋 真美子, Shiroh Fujii, Shingen Nakamura, Hirokazu Miki, Kumiko Kagawa, Mio Yada, Yoshihiro Matsudate, Hisanori Uehara and Masahiro Abe :
少量methotrexate療法が有効であった進行期原発性皮膚未分化大細胞型リンパ腫.,
The Japanese Journal of Clinical Hematology, Vol.63, No.6, 536-543, Mar. 2022.
(DOI: 10.11406/rinketsu.63.536)
23. 高原 由実子, Hirokazu Miki, Shingen Nakamura, 中村 昌史, Ryohei Sumitani, Masahiro Oura, Kimiko Sogabe, 髙橋 真美子, 丸橋 朋子, 岡本 秀樹, Naoto Okada, 矢野 由美子, 高橋 真理, Takeshi Harada, Shiroh Fujii, Keiko Aota, Shuji Ozaki and Masahiro Abe :
HIV感染症および後天性免疫不全症候群患者の臨床的特徴と今後の課題., --- 264 ( 3 ) ---,
第264回徳島医学会学術集会(令和3年度冬期), 2022年2月20日(Web開催), Feb. 2022.
24. Hiroki Yamada, Rio Ohmori, Naoto Okada, Shingen Nakamura, Kumiko Kagawa, Shiroh Fujii, Hirokazu Miki, Keisuke Ishizawa, Masahiro Abe and Youichi Sato :
ゲノムワイド関連解析によるビンクリスチン副作用発現関連遺伝子の同定と機械学習を用いた副作用発現予測モデルの構築,
第60回日本薬学会中国四国支部学術大会, Nov. 2021.
25. Kimiko Sogabe, Takeshi Harada, Shingen Nakamura, Hirokazu Miki, 小田 明日香, 井上 雄介, Ryohei Sumitani, 丸橋 朋子, Masahiro Oura, Shiroh Fujii, Kumiko Kagawa, Hirofumi Tenshin, Masahiro Hiasa, Jumpei Teramachi and Masahiro Abe :
Resumption of myeloma cell sensitivity to proteasome inhibitors by PIM and Akt inhibition,
The 83rd Annual Meeting of the Japanese Society of Hematology, Sep. 2021.
26. Takeshi Harada, Yusuke Inoue, Hirofumi Tenshin, Asuka Oda, Ryohei Sumitani, Masahiro Oura, Kimiko Sogabe, Shiroh Fujii, Shingen Nakamura, Hirokazu Miki, Kumiko Kagawa, Masahiro Hiasa, Jumpei Teramachi and Masahiro Abe :
Expansion of γδT cells by CELMoDs and enhancement of their anti-myeloma effects by elotuzumab,
The 83rd Annual Meeting of Japanese Society of Hematology, Sep. 2021.
27. Shingen Nakamura, 上野 宜久, Sumiko Yoshida, 中村 昌史, 水口 槙子, Ryohei Sumitani, Masahiro Oura, Kimiko Sogabe, 高橋 真美子, 丸橋 朋子, Takeshi Harada, Shiroh Fujii, Hirokazu Miki, Kumiko Kagawa, 広津 崇亮 and Masahiro Abe :
血液がんにおける線虫がん検査 N-NOSEの検討(Detection of hematological malignancies using N-NOSE(Nematode-NOSE)),
日本血液学会学術集会, OS1-11B-2, Sep. 2021.
28. Hirokazu Miki, Shingen Nakamura, Shiroh Fujii, 中村 昌史, 水口 槙子, Ryohei Sumitani, Masahiro Oura, Kimiko Sogabe, 髙橋 真美子, 丸橋 朋子, Takeshi Harada, Kumiko Kagawa, Nishio Susumu, Tetsu Tomonari and Masahiro Abe :
肝臓アミロイドーシスに対する超音波エラストグラフィの診断的有用性.,
第83回日本血液学会学術集会, OS1-8D-2, Sep. 2021.
29. Kimiko Sogabe, Takeshi Harada, Shingen Nakamura, Hirokazu Miki, 小田 明日香, 井上 雄介, Ryohei Sumitani, 丸橋 朋子, Masahiro Oura, Shiroh Fujii, Kumiko Kagawa, Hirofumi Tenshin, Masahiro Hiasa, Jumpei Teramachi and Masahiro Abe :
PIMとAkt阻害による骨髄腫細胞のプロテアソーム阻害薬感受性の増強(Sensitization of myeloma cells to proteasome inhibitors by PIM and Akt inhibition),
日本血液学会学術集会, OS2-11D-3, Sep. 2021.
30. Takeshi Harada, Yusuke Inoue, Hirofumi Tenshin, Asuka Oda, Ryohei Sumitani, Masahiro Oura, Kimiko Sogabe, Shiroh Fujii, Shingen Nakamura, Hirokazu Miki, Kumiko Kagawa, Masahiro Hiasa, Jumpei Teramachi and Masahiro Abe :
Development of combinatory treatment of Th1-like γδT cells with elotuzumab against osteoclasts as well as myeloma cells,
第46回日本骨髄腫学会学術集会, May 2021.
31. Kimiko Sogabe, Takeshi Harada, Shingen Nakamura, Hirokazu Miki, 小田 明日香, 井上 雄介, Ryohei Sumitani, Masahiro Oura, Shiroh Fujii, Kumiko Kagawa, Hirofumi Tenshin, Masahiro Hiasa, Jumpei Teramachi, 李 政樹, 飯田 真介 and Masahiro Abe :
骨髄腫細胞のプロテアソーム阻害薬の耐性機序におけるPIM2とAkt活性およびNRF2蓄積の役割(Mechanisms for the resistance to proteasome inhibitors in myeloma cells: the role of PIM2 and Akt kinase activation and NRF2 accumulation),
International Journal of Myeloma, Vol.11, No.2, 85, May 2021.
32. 石田 卓也, Hirokazu Miki, 髙橋 真美子, 中村 昌史, 水口 槙子, Ryohei Sumitani, Masahiro Oura, Kimiko Sogabe, 丸橋 朋子, 岡本 秀樹, Naoto Okada, 矢野 由美子, 高橋 真理, Tetsu Tomonari, Takeshi Harada, Shiroh Fujii, Shingen Nakamura, Kumiko Kagawa, Keiko Aota, Hiroyoshi Watanabe and Masahiro Abe :
HIV感染血友病患者における臨床的特徴と今後の課題,
第262回徳島医学会学術集会, Mar. 2021.
33. Maruhashi Tomoko, Shiroh Fujii, Kumiko Kagawa, Nakamura Masafumi, Shiyori Kawata, Makiko Mizuguchi, Ryohei Sumitani, Masahiro Oura, Kimiko Sogabe, Takahashi Mamiko, Takeshi Harada, Shingen Nakamura, Hirokazu Miki and Masahiro Abe :
造血幹細胞移植(allo-SCT)が奏効したMLL遺伝子変異合併CML急性転化(CML-BP)の2例,
第43回日本造血細胞移植学会総会, Mar. 2021.
34. Minori Takei, Naoto Okada, Shingen Nakamura, Kumiko Kagawa, Shiroh Fujii, Hirokazu Miki, Keisuke Ishizawa, Masahiro Abe and Youichi Sato :
機械学習による遺伝情報を用いた抗がん剤投与の味覚障害発現予測モデルの構築,
第59回中国四国支部学術大会, Dec. 2020.
35. Yuka Endoh, Hozumi Tashima, 岡田 直人, Shingen Nakamura, Kumiko Kagawa, Shiroh Fujii, Hirokazu Miki, Keisuke Ishizawa, Masahiro Abe and Youichi Sato :
ゲノム情報を用いた機械学習によるシタラビン投与後の副作用発現予測モデルの構築,
第59回中国四国支部学術大会, Dec. 2020.
36. 清重 尚希, Ryohei Sumitani, 水口 槙子, 中村 昌史, Masahiro Oura, Kimiko Sogabe, 高橋 真美子, Takeshi Harada, Shiroh Fujii, 賀川 久美子, Masahiro Abe, Shingen Nakamura, Hirokazu Miki, 曽賀 愛未, 一宮 由貴 and Yuri Yamamoto :
急性転化をきたしたAYA世代慢性骨髄性白血病の1例,
Shikoku Acta Medica, Vol.76, No.5-6, 354-355, Dec. 2020.
37. Hirokazu Miki, 悦子 李, 佃 恵里加, 小田 直輝, 瀧本 朋美, 中村 昌史, 水口 槙子, Ryohei Sumitani, Masahiro Oura, Kimiko Sogabe, 高橋 真美子, Takeshi Harada, Shiroh Fujii, Kumiko Kagawa, Masahiro Abe and Shingen Nakamura :
Daratumumab投与による輸血関連検査への影響とその対策,
Shikoku Acta Medica, Vol.76, No.5-6, 341, Dec. 2020.
38. 中村 昌史, Shiroh Fujii, Hirokazu Miki, 細木 美苗, Kimiko Sogabe, 髙橋 真美子, 丸橋 朋子, 大櫛 祐一郎 and Masahiro Abe :
ACE阻害薬による血管性浮腫が原因と考えられた喉頭浮腫の一例,
第123回日本内科学会四国地方会, Nov. 2020.
39. 丸橋 朋子, Hirokazu Miki, 中村 昌史, 高橋 真美子, Shiroh Fujii, 中野 綾子 and Masahiro Abe :
Evans症候群に合併した自己免疫性骨髄線維症の1例,
第123回日本内科学会四国地方会, Nov. 2020.
40. 市原 聖也, Ryohei Sumitani, 中村 昌史, 水口 槙子, Takeshi Harada, Shiroh Fujii, Shingen Nakamura, Hirokazu Miki, Kumiko Kagawa and Masahiro Abe :
ウイルス関連血球貪食症候群が疑われたアグレッシブNK細胞白血病の1例,
第123回日本内科学会四国地方会, Nov. 2020.
41. Akane Abe, Nobuhito Naito, Kenji Otsuka, Yukikiyo Kawakami, Shiroh Fujii, Seiji Iwamoto, Seidai Satou, Hiroshi Kawano, Hiroshi Nokihara and Yasuhiko Nishioka :
非小細胞肺癌に合併した後天性血友病Aの1例,
第123回日本内科学会四国地方会, Nov. 2020.
42. Kimiko Sogabe, Shingen Nakamura, Shiroh Fujii, Hirokazu Miki, 小田 明日香, Takeshi Harada, Ryohei Sumitani, Masahiro Oura, Kumiko Kagawa, Hirofumi Tenshin, Jumpei Teramachi, Masaki Ri, Shinsuke Iida and Masahiro Abe :
Immediate accumulation of anti-apoptotic PIM2 in myeloma cells by proteasome inhibitors,
第82回日本血液学会学術集会, Oct. 2020.
43. Masahiro Ohhra, Takeshi Harada, 寺町 順平, 小田 明日香, Yusuke Inoue, Kimiko Sogabe, Ryohei Sumitani, Shiroh Fujii, Shingen Nakamura, Hirokazu Miki, Kumiko Kagawa, Hasegawa Hiroo, Fujiwara Hiroshi and Masahiro Abe :
Critical roles of the TAK1-c-Myc loop as a novel therapeutic target for ATL,
第82回日本血液学会学術集会, Oct. 2020.
44. Takeshi Harada, Yusuke Inoue, Hirofumi Tenshin, Asuka Oda, Masahiro Oura, Kimiko Sogabe, Ryohei Sumitani, Shiroh Fujii, Shingen Nakamura, Hirokazu Miki, Kumiko Kagawa, Masahiro Hiasa, Jumpei Teramachi and Masahiro Abe :
Versatile anti-myeloma effects by elotuzumab: impact on γδT cells and osteoclasts,
The 82nd Annual Meeting of Japanese Soceity of Hematology, Oct. 2020.
45. Masahiro Oura, Shingen Nakamura, 堀 太貴, Kimiko Sogabe, Takeshi Harada, Shiroh Fujii, Hirokazu Miki, Kumiko Kagawa, Tomoko Kobayashi, Takeshi Oya and Masahiro Abe :
結節性紅斑と悪性腫瘍関連血球貪食症候群を惹起した骨髄異形成症候群の1例,
The Japanese Journal of Clinical Hematology, Vol.61, No.10, 1542, Oct. 2020.
46. 中村 昌史, Hirokazu Miki, Masahiro Oura, 川田 知代, 堀 太貴, 村井 純平, Ryohei Sumitani, Kimiko Sogabe, 高橋 真美子, Takeshi Harada, Shiroh Fujii, Shingen Nakamura, Kumiko Kagawa, 菅崎 幹樹, 徳永 尚樹, Akishige Ikegame, 森下 英理子 and Masahiro Abe :
クロスミキシングテストの特徴的な所見が診断の契機となったプレカリクレイン欠乏症の1例,
The Japanese Journal of Clinical Hematology, Vol.61, No.10, 1537-1538, Oct. 2020.
47. 村井 純平, 堀 太貴, 川田 知代, Ryohei Sumitani, 宇高 憲吾, Takeshi Harada, Shiroh Fujii, Shingen Nakamura, Kumiko Kagawa, Masahiro Abe, Hirokazu Miki, 桝田 志保, Itsuro Endo and Seiji Fukumoto :
高ビタミンD血症による高Ca血症を来したホジキンリンパ腫の一例,
Shikoku Acta Medica, Vol.76, No.1-2, 124, Apr. 2020.
48. Yuka Endoh, Hozumi Tashima, Naoto Okada, Shingen Nakamura, Kumiko Kagawa, Shiroh Fujii, Hirokazu Miki, Keisuke Ishizawa, Masahiro Abe and Youichi Sato :
機械学習を用いたゲノム情報によるシタラビン投与の副作用発現予測モデルの構築,
日本薬学会 第140年会, Mar. 2020.
49. Minori Takei, Naoto Okada, Shingen Nakamura, Kumiko Kagawa, Shiroh Fujii, Hirokazu Miki, Keisuke Ishizawa, Masahiro Abe and Youichi Sato :
遺伝情報を用いた機械学習による抗がん剤投与の味覚障害発現予測モデルの構築,
日本薬学会 第140年会, Mar. 2020.
50. 遠藤 優香, 田島 穂澄, Naoto Okada, Shingen Nakamura, Kumiko Kagawa, Shiroh Fujii, Hirokazu Miki, Keisuke Ishizawa, Masahiro Abe and Youichi Sato :
機械学習を用いたゲノム情報によるシタラビン投与の副作用発現予測モデルの構築,
日本薬学会年会要旨集, 26M-am07S, Mar. 2020.
51. 安宅 克博, Shingen Nakamura, Masahiro Oura, Kimiko Sogabe, Takeshi Harada, Shiroh Fujii, Hirokazu Miki, Kumiko Kagawa, Yasuhiko Nishioka and Masahiro Abe :
長期にわたる血小板減少が先行した芽球性形質細胞様樹状細胞腫瘍の1例,
第120回日本内科学会四国地方会, May 2019.
52. Takeshi Harada, Oda Asuka, Hirofumi Tenshin, Jumpei Teramachi, Masahiro Oura, Kimiko Sogabe, Masami Iwasa, Shiroh Fujii, Hirokazu Miki, Kumiko Kagawa, Teru Hideshima, Anderson C. Kenneth and Masahiro Abe :
The novel therapeutic strategy targeting the HDAC1-IRF4-PIM2 pathway in myeloma cells,
The 44th Annual Meeting of the Japanese Society of Myeloma, May 2019.
53. Yuto Tanigaki, Yuta Yamaguchi, Naoto Okada, Shingen Nakamura, Kumiko Kagawa, Shiroh Fujii, Hirokazu Miki, Keisuke Ishizawa, Masahiro Abe and Youichi Sato :
ゲノムワイド関連解析を用いたテイコプラニン・バンコマイシン投与による皮疹発現および血中濃度関連遺伝子座の同定,
日本薬学会 第139年会, Mar. 2019.
54. Rio Ohmori, Naoto Okada, Shingen Nakamura, Kumiko Kagawa, Shiroh Fujii, Hirokazu Miki, Keisuke Ishizawa, Masahiro Abe and Youichi Sato :
ゲノムワイド関連解析を用いたビンクリスチンによる末梢神経障害発現関連遺伝子の同定,
第57回日本薬学会・日本薬剤師会・日本病院薬剤師会 中国四国支部学術大会, Nov. 2018.
55. Yuta Yamaguchi, Yuto Tanigaki, Naoto Okada, Shingen Nakamura, Kumiko Kagawa, Shiroh Fujii, Hirokazu Miki, Keisuke Ishizawa, Masahiro Abe and Youichi Sato :
CYP遺伝子多型とバンコマイシンの副作用発現及び血中濃度との関連解析,
第57回日本薬学会・日本薬剤師会・日本病院薬剤師会 中国四国支部学術大会, Nov. 2018.
56. Jumpei Teramachi, Hirofumi Tenshin, Masahiro Hiasa, Oda Asuka, Bat-Erdene Ariunzaya, Takeshi Harada, Iwasa Masami, Shiroh Fujii, Kimiko Sogabe, Shingen Nakamura, Hirokazu Miki, Masahiro Oura, Kumiko Kagawa, Itsuro Endo, Toshio Matsumoto and Masahiro Abe :
Mechanisms of TAK1 over-activation in myeloma cells and TAK1-mediated myeloma growth and bone destruction,
第80回日本血液学会学術集会, Oct. 2018.
57. Masami Iwasa, Takeshi Harada, Bat-Erdene Ariunzaya, 小田 明日香, Kimiko Sogabe, Masahiro Oura, Jumpei Teramachi, Shiroh Fujii, Shingen Nakamura, Hirokazu Miki, Kumiko Kagawa and Masahiro Abe :
HDAC阻害による骨髄腫細胞のIFN-γ-STAT1- PD-L1経路の増強効果,
第80回日本血液学会学術集会, Oct. 2018.
58. Ashtar Mohannad, Hirofumi Tenshin, Jumpei Teramachi, Masahiro Hiasa, Kotaro Tanimoto, Oda Asuka, Iwasa Masami, Takeshi Harada, Ariunzaya Erdene Bat, Kimiko Sogabe, Oura Masahiro, Shiroh Fujii, Kumiko Kagawa, Shingen Nakamura, Hirokazu Miki, Eiji Tanaka, Toshio Matsumoto and Masahiro Abe :
Roles of ROS in induction of bone disease and cancer treatment-induced bone loss in myeloma.,
The 80th Annual Meeting of the Japanese Society of Hematology, Oct. 2018.
59. Hirofumi Tenshin, Jumpei Teramachi, Masahiro Hiasa, Kotaro Tanimoto, Mohannad Ashtar, Ariunzaya Bat-Erdene, Iwasa Masami, Takeshi Harada, Shingen Nakamura, Hirokazu Miki, Kimiko Sogabe, Oura Masahiro, Shiroh Fujii, Kumiko Kagawa, Itsuro Endo, Eiji Tanaka, Toshio Matsumoto and Masahiro Abe :
Inverse regulation of c-FLIP-mediated survival in myeloma cells and osteoclasts by TRAIL.,
The 80th Annual Meeting of the Japanese Society of Hematology, Oct. 2018.
60. Masahiro Hiasa, Jumpei Teramachi, Hirofumi Tenshin, Kotaro Tanimoto, Ariunzaya Bat-Erdene, Mohannad Ashtar, Masami Iwasa, Takeshi Harada, Shingen Nakamura, Hirokazu Miki, Kimiko Sogabe, Oura Masahiro, Shiroh Fujii, Kumiko Kagawa, Oda Asuka, Itsuro Endo, Eiji Tanaka, Toshio Matsumoto and Masahiro Abe :
The effects of cathepsin K inhibition on osteocytes: its role in bone restoration in MM bone disease.,
The 80th Annual Meeting of the Japanese Society of Hematology, Oct. 2018.
61. Masami Iwasa, Takeshi Harada, Bat-Erdene Ariunzaya, 小田 明日香, 前田 悠作, 高橋 真美子, Masahiro Oura, Jumpei Teramachi, Shiroh Fujii, Shingen Nakamura, Hirokazu Miki, Kumiko Kagawa and Masahiro Abe :
Amplification of the IFN- γ -STAT1- PD-L1 pathway in myeloma cells by panobinostat,
The 43rd Annual Meeting of the Japanese Society of Myeloma, May 2018.
62. Takeshi Harada, Oda Asuka, Jumpei Teramachi, Bat-Erdene Ariunzaya, Iwasa Masami, Maeda Yusaku, Shingen Nakamura, Oura Masahiro, Shiroh Fujii, Hirokazu Miki, Kumiko Kagawa, Hideshima Teru, Anderson C. Kenneth and Masahiro Abe :
HDAC1/3 inhibition disrupts the IRF4-Pim-2 pathway to induce effective myeloma cell death,
The 43rd Annual Meeting of the Japanese Society of Myeloma, May 2018.
63. Yuto Tanigaki, Youichi Sato, Yuta Yamaguchi, Naoto Okada, Shingen Nakamura, Kumiko Kagawa, Shiroh Fujii, Hirokazu Miki, Keisuke Ishizawa, Masahiro Abe and Aiko Yamauchi :
テイコプラニン投与による副作用発現および血中濃度とCYP遺伝子多型との関連解析,
第56回日本薬学会・日本薬剤師会・日本病院薬剤師会 中国四国支部学術大会, Oct. 2017.
64. Hozumi Tashima, Youichi Sato, Naoto Okada, Shingen Nakamura, Kumiko Kagawa, Shiroh Fujii, Hirokazu Miki, Keisuke Ishizawa, Masahiro Abe and Aiko Yamauchi :
シタラビン投与による副作用発現と代謝経路関連遺伝子多型の関連解析,
第56回日本薬学会・日本薬剤師会・日本病院薬剤師会 中国四国支部学術大会, Oct. 2017.
65. Jumpei Teramachi, Masahiro Hiasa, Oda Asuka, Hirofumi Tenshin, Ryota Amachi, Takeshi Harada, Shingen Nakamura, Masami Iwasa, Masahiro Oura, Yusaku Maeda, Shiroh Fujii, Kumiko Kagawa, Hirokazu Miki, Itsuro Endo, Toshio Matsumoto and Masahiro Abe :
Disruption of myeloma cell-bone marrow interaction by TAK-1 inhibition,
第80回日本血液学会学術集会, Oct. 2017.
66. Hirofumi Tenshin, Jumpei Teramachi, 小田 明日香, Ryota Amachi, Masahiro Hiasa, Keiichiro Watanabe, Ariunzaya Baterdene, Masami Iwasa, Shiroh Fujii, Kumiko Kagawa, Shingen Nakamura, Hirokazu Miki, Itsuro Endo, Eiji Tanaka, Toshio Matsumoto and Masahiro Abe :
TRAILは破骨細胞を活性化させるが,TAK1阻害により骨髄腫細胞とともに破骨細胞にもTRAILのアポトーシス誘導活性が惹起できる,
The 35th Annual Meeting of the Japanese Society for Bone and Mineral Research (oral talk), Jul. 2017.
67. Rio Ohmori, Youichi Sato, Misaki Kiguchi, Naoto Okada, Shingen Nakamura, Kumiko Kagawa, Shiroh Fujii, Hirokazu Miki, Keisuke Ishizawa, Masahiro Abe and Aiko Yamauchi :
ビンクリスチンによる副作用発現とMDR1遺伝子多型との関連性,
第20回日本医薬品情報学会総会・学術大会, Jul. 2017.
68. Yuta Yamaguchi, Youichi Sato, Yuto Tanigaki, Naoto Okada, Shingen Nakamura, Kumiko Kagawa, Shiroh Fujii, Hirokazu Miki, Keisuke Ishizawa, Masahiro Abe and Aiko Yamauchi :
バンコマイシン投与による副作用発現及び血中濃度とCYP遺伝子多型との関連解析,
第20回日本医薬品情報学会総会・学術大会, Jul. 2017.
69. 天知 良太, Shingen Nakamura, Masahiro Hiasa, 小田 明日香, バットエルデネ アリウンザヤ, Jumpei Teramachi, Hirofumi Tenshin, Keiichiro Watanabe, Hirokazu Miki, Kumiko Kagawa, Shiroh Fujii, Eiji Tanaka, Toshio Matsumoto and Masahiro Abe :
骨形成誘導による骨髄腫細胞のエネルギー代謝の抑制,
第42回日本骨髄腫学会学術集会, May 2017.
70. 岡本 恵暢, Shingen Nakamura, 上村 宗範, Ryohei Sumitani, 高橋 真美子, Shiroh Fujii, Kumiko Kagawa, Masahiro Abe and Hirokazu Miki :
発熱と下肢対麻痺で発症した血管内大細胞型B細胞性リンパ腫の2例,
Shikoku Acta Medica, Vol.72, No.5-6, 236-237, Dec. 2016.
71. Jumpei Teramachi, Hiroshi Mori, Yasuo Ochi, Ryota Amachi, Asuka Oda, Masahiro Hiasa, Takeshi Harada, Shiroh Fujii, Shingen Nakamura, Hirokazu Miki, Kumiko Kagawa, Itsuro Endo, Eiji Tanaka, Toshio Matsumoto and Masahiro Abe :
Potent induction of bone formation by anti-resorptive cathepsin K inhibitor in myeloma.,
The 77th Annual Meeting of the Japanese Society of Hematology, Oct. 2016.
72. Ryota Amachi, Masahiro Hiasa, Jumpei Teramachi, 小田 明日香, Hirofumi Tenshin, Keiichiro Watanabe, Shingen Nakamura, Hirokazu Miki, Kumiko Kagawa, Shiroh Fujii, 遠藤 逸郎, Eiji Tanaka, Toshio Matsumoto and Masahiro Abe :
Mechanism of the TRPV1 up-regulatation in myeloma cells and adaptation to an acidic microenvironment.,
第77回日本血液学会学術集会,, Oct. 2016.
73. Jumpei Teramachi, Masahiro Hiasa, 小田 明日香, 原田 武志, Hirofumi Tenshin, Shingen Nakamura, Ryota Amachi, Shiroh Fujii, Keiichiro Watanabe, Kumiko Kagawa, Hirokazu Miki, Itsuro Endo, Tatsuji Haneji, Toshio Matsumoto and Masahiro Abe :
Pim-2は骨髄腫における破骨細胞形成促進の 必須媒介因子である,
第41回日本骨髄腫学会学術集会, May 2016.
74. Ryota Amachi, Masahiro Hiasa, Jumpei Teramachi, A Oda, Hirofumi Tenshin, Keiichiro Watanabe, Shingen Nakamura, H Miki, Kumiko Kagawa, Shiroh Fujii, Eiji Tanaka, Toshio Matsumoto and Masahiro Abe :
Mechanism of the TRPV1 up-regulatation in myeloma cells and adaptation to an acidic microenvironment,
第77回日本血液学会学術集会, Oct. 2015.
75. Keiichiro Watanabe, Jumpei Teramachi, H Mori, Y Ochi, Ryota Amachi, A Oda, Masahiro Hiasa, T Harada, Shiroh Fujii, Shingen Nakamura, H Miki, Kumiko Kagawa, Itsuro Endo, Eiji Tanaka, Toshio Matsumoto and Masahiro Abe :
Potent induction of bone formation by anti-resorptive cathepsin K inhibitor in myeloma,
第77回日本血液学会学術集会, Oct. 2015.
76. Jumpei Teramachi, Masahiro Hiasa, Asuka Oda, Hirofumi Tenshin, Ryota Amachi, Takeshi Harada, Keiichiro Watanabe, Shiroh Fujii, Kumiko Kagawa, Shingen Nakamura, Hirokazu Miki, Itsuro Endo, Tatsuji Haneji, Toshio Matsumoto and Masahiro Abe :
Potent suppression of osteoclastogenesis in myeloma by Pim inhibition,
第77回日本血液学会学術集会, Oct. 2015.
77. Jumpei Teramachi, Masahiro Hiasa, Asuka Oda, Hirofumi Tenshin, Ryota Amachi, Takeshi Harada, Keiichiro Watanabe, Shiroh Fujii, Kumiko Kagawa, Shingen Nakamura, Hirokazu Miki, Itsuro Endo, Tatsuji Haneji, Toshio Matsumoto and Masahiro Abe :
Tumor reduction and bone restoration in myeloma by TAK-1 inhibition,
第77回日本血液学会学術集会, Oct. 2015.
78. Ryota Amachi, Masahiro Hiasa, Jumpei Teramachi, 小田 明日香, Hirofumi Tenshin, Keiichiro Watanabe, Shingen Nakamura, Kumiko Kagawa, Hirokazu Miki, Shiroh Fujii, Itsuro Endo, Eiji Tanaka, Toshio Matsumoto and Masahiro Abe :
酸環境での骨髄腫細胞のDR4発現抑制:酸によるエピジェネティックな遺伝子発現制御,
第1回日本骨免疫学会, 108, Jul. 2015.
79. Jumpei Teramachi, Masahiro Hiasa, 小田 明日香, 原田 武志, Ryota Amachi, Hirofumi Tenshin, Hirokazu Miki, Shingen Nakamura, Shiroh Fujii, Kumiko Kagawa, Itsuro Endo, Toshio Matsumoto and Masahiro Abe :
Pim阻害による骨髄腫骨吸収亢進の抑制,
第40回日本骨髄腫学会学術集会, May 2015.
80. Jumpei Teramachi, Masahiro Hiasa, 小田 明日香, 原田 武志, Ryota Amachi, Hirofumi Tenshin, Hirokazu Miki, Shingen Nakamura, Shiroh Fujii, Kumiko Kagawa, Itsuro Endo, Toshio Matsumoto and Masahiro Abe :
TAK-1は骨髄腫腫瘍進展と骨破壊病変形成の枢軸的な媒介因子である,
第40回日本骨髄腫学会学術集会, May 2015.
81. 丸橋 朋子, Shingen Nakamura, 曽我部 公子, 八木 ひかる, 高橋 真美子, 宇高 憲吾, Shiroh Fujii, Hirokazu Miki, Kumiko Kagawa, Masahiro Abe, Atsuro Saijo, Mayuri Nakano, Momoyo Azuma, Yasuhiko Nishioka, 近藤 憲保, 井内 新, 藤田 博己 and 馬原 文彦 :
当院で経験した重症熱性血小板減少症候群の3例,
第250回徳島医学会学術集会, Feb. 2015.
82. Jumpei Teramachi, Masahiro Hiasa, 原田 武志, Ryota Amachi, Kumiko Kagawa, Hirokazu Miki, Shingen Nakamura, Shiroh Fujii, Itsuro Endo, Toshio Matsumoto and Masahiro Abe :
Therapeutic impact of Pim inhibition on myeloma bone disease: blockade of NF-B-mediated suppression of osteoblastogenesis and stimulation of osteoclastogenesis,
日本血液学会, Oct. 2014.
83. Keiichiro Watanabe, Masahiro Abe, H Mori, K Udaka, M Iwasa, D Hanson, Ryota Amachi, Masahiro Hiasa, T Harada, Shiroh Fujii, Shingen Nakamura, H Miki, Kumiko Kagawa, Itsuro Endo, Eiji Tanaka and Toshio Matsumoto :
Bone restoration and tumor suppression in myeloma by cathepsin K inhibition with Bortezomib,
第75回日本血液学会学術集会, Oct. 2013.
84. 大黒 由加里, Takeshi Kondo, Shiroh Fujii, Shingen Nakamura, 倉橋 清衛, Akio Kuroda, Itsuro Endo, Ken-ichi Aihara, Munehide Matsuhisa and Toshio Matsumoto :
著名な汎血球減少と肝筋逸脱酵素高値を呈した神経性食欲不振症の一例,
第13回日本内分泌学会四国支部学術集会, Sep. 2013.
85. Ryota Amachi, Keiichiro Watanabe, Shiroh Fujii, T Harada, H Miki, S Nakamura, A Oda, Masahiro Hiasa, Eiji Tanaka, Toshio Matsumoto and Masahiro Abe :
An acdic milieu confers the resistance to TRAIL in myeloma cells through the PI3K-Akt-mediated epigenetic down-regulation of the TRAIL receptor DR4,
International Bone and Mineral Society 2013, May 2013.
86. Keiichiro Watanabe, Masahiro Abe, H Mori, Ryota Amachi, Masahiro Hiasa, T Harada, Shiroh Fujii, S Nakamura, H Miki, K Kagawa, I Endo, Eiji Tanaka and Toshio Matsumoto :
Induction of cathepsin K induce bone formation in myeloma osteolytic lesions,
International Bone and Mineral Society 2013, May 2013.
87. Ryota Amachi, Keiichiro Watanabe, Shiroh Fujii, T Harada, H Miki, S Nakamura, A Oda, Masahiro Hiasa, Eiji Tanaka, Toshio Matsumoto and Masahiro Abe :
An acdic milieu suppresses histone acetylation in myeloma cells to down-regulate the TRAIL receptor DR4 expression,
14th International Myeloma Workshop, Apr. 2013.
88. Keiichiro Watanabe, Masahiro Abe, Ryota Amachi, Masahiro Hiasa, T Harada, Shiroh Fujii, S Nakamura, H Miki, K Kagawa, I Endo, Eiji Tanaka and Toshio Matsumoto :
Induction of bone formation in myeloma osteolytic lesions by cathepsin K inhibition,
14th International Myeloma Workshop, Apr. 2013.
89. Hirokazu Miki, Shingen Nakamura, 竹内 恭子, 原田 武志, 岩佐 昌美, Shiroh Fujii, Kumiko Kagawa, Masahiro Abe and Toshio Matsumoto :
赤芽球癆を合併した多中心性Castleman病の1例,
日本内科学会第107回四国地方会, Dec. 2012.
90. Shiroh Fujii, Masahiro Abe, Ryota Amachi, Keiichiro Watanabe, Masahiro Hiasa, 竹内 恭子, 岩佐 昌美, 原田 武志, Shingen Nakamura, Hirokazu Miki, Kumiko Kagawa and Toshio Matsumoto :
Pim inhibition preferentially induces anti-myeloma activity in an acidic milien,
第74回日本血液学会学術集会, Oct. 2012.
91. 原田 武志, Shuji Ozaki, 岩佐 昌美, Shiroh Fujii, Shingen Nakamura, Hirokazu Miki, Kumiko Kagawa, 柴田 泰伸, 重清 俊雄, 岡田 直人, 長尾 多美子, 鈴木 麗子, Shoji Sakiyama, Masahiro Abe and Toshio Matsumoto :
徳島県のエイズ拠点病院におけるHIV感染症及び後天性免疫不全症候群の現状,
第245回徳島県医学会学術総会, Jul. 2012.
92. 大黒 由加里, Shingen Nakamura, 岩佐 昌美, 原田 武志, Shiroh Fujii, Kumiko Kagawa, Masahiro Abe, Toshio Matsumoto and Hirokazu Miki :
腰痛と副腎不全症状で発症した両側副腎原発DLBCLの1例,
日本内科学会第106回四国地方会, Jun. 2012.
93. 原田 武志, Shiroh Fujii, Shingen Nakamura, Hirokazu Miki, 中野 綾子, Kumiko Kagawa, 竹内 恭子, Masahiro Abe and Toshio Matsumoto :
徳島県における多発性骨髄腫の治療成績の検討,
第109回日本内科学会総会・講演会, Apr. 2012.
94. 原田 武志, Shuji Ozaki, 小田 明日香, 天羽 宏枝, Shiroh Fujii, Shingen Nakamura, Hirokazu Miki, 中野 綾子, Kumiko Kagawa, 竹内 恭子, Masahiro Abe, 柴田 泰伸 and Toshio Matsumoto :
Lenalidomide 治療中の多発性骨髄腫患者におけるCRP上昇の検討,
第51回日本血液学会中国四国地方会, Mar. 2012.
95. Kumiko Kagawa, 原田 武志, Shiroh Fujii, Shingen Nakamura, Hirokazu Miki, 竹内 恭子, Masahiro Abe and Toshio Matsumoto :
遺伝子組み替えヒトトロンボモジュリン投与中に硬膜下血腫を来した同腫骨髄移植2症例,
第34回日本造血細胞移植学会, Feb. 2012.
96. Kumiko Kagawa, 原田 武志, Shiroh Fujii, Shingen Nakamura, Hirokazu Miki, 竹内 恭子, Masahiro Abe and Toshio Matsumoto :
遺伝子組み換えヒトトロンボモジュリン投与中に硬膜下血腫を来した同腫骨髄移植2症例,
第34回日本造血細胞移植学会, Feb. 2012.
97. Keiichiro Watanabe, Masahiro Abe, Q Cui, Masahiro Hiasa, M Kawatani, T Harada, Shiroh Fujii, Shingen Nakamura, Hirokazu Miki, A Nakano, K Kagawa, K Takeuchi, H Osada, Eiji Tanaka and Toshio Matsumoto :
Targeting an acidic microenvironment by reveromycin A to overcome drug resistance to myeloma cells and ameliorate bone disease.,
第36回日本骨髄腫研究会総会, Nov. 2011.
98. Keisuke Fujioka, Atsuro Saijo, Yuko Toyoda, Souji Kakiuchi, Masaki Hanibuchi, Masahiko Azuma, Yasuhiko Nishioka, Kyoko Takeuchi, Shiroh Fujii, Shingen Nakamura, Kumiko Kagawa, Masahiro Abe and Tomoya Mizutani :
不明熱で発症し皮膚生検が診断に有効であった血管内リンパ腫の1例,
第243回徳島医学会学術集会, Jul. 2011.
99. Keiichiro Watanabe, Masahiro Abe, Cui Qu, Kawatani Makoto, Masahiro Hiasa, Nakano Ayako, Jinno Tadashi, Harada Takeshi, Shiroh Fujii, Shingen Nakamura, Miki Hirokazu, Kumiko Kagawa, Kyoko Takeuchi, Shuji Ozaki, Eiji Tanaka, Osada Hiroyuki and Toshio Matsumoto :
Reveromycin A prevents bone destruction and suppresses tumor growth in myeloma,
第72回日本血液学会, Dec. 2010.
100. 宇高 憲吾, Naoko Matsui, 宮本 亮介, Yuka Terasawa, Kenta Sato, Koutaro Asanuma, Yuishin Izumi, Ryuji Kaji, Shiroh Fujii, Kyoko Takeuchi, Masahiro Abe and Masafumi Harada :
多発性骨髄腫の経過中に進行性多巣性白質脳症をきたした一例,
Shikoku Acta Medica, Vol.66, No.5-6, 198, Dec. 2010.
101. Kumiko Kagawa, Jinno Tasashi, Harada Kakeshi, Cui Qu, Keiichiro Watanabe, Masahiro Hiasa, Oda Asuka, Amo Hiroe, Akishige Ikegame, Miki Hirokazu, Shiroh Fujii, Nakano Ayako, Kyoko Takeuchi, Shuji Ozaki, Masahiro Abe and Toshio Matsumoto :
Sensitization of hematopietic malignant cells to TRAIL with bortezomib and a TACE inhibitor,
第72回日本血液学会, Sep. 2010.
102. Shingen Nakamura, Masahiro Abe, Cui Qu, Keiichiro Watanabe, Akishige Ikegame, Masahiro Hiasa, Miki Hirokazu, Nakano Ayako, Oda Asuka, Amo Hiroe, Jinno Tasashi, Harada Takeshi, Shiroh Fujii, Kumiko Kagawa, Kyoko Takeuchi, Shuji Ozaki and Toshio Matsumoto :
Bortezomib-induced osteoblast differentiation is hampered by excessive ER stress,
第72回日本血液学会, Sep. 2010.
103. Cui Qu, Masahiro Abe, Miki Hirokazu, Shingen Nakamura, Keiichiro Watanabe, Akishige Ikegame, Masahiro Hiasa, Nakano Ayako, Jinnno Tadashi, Harada Takeshi, Shiroh Fujii, Kumiko Kagawa, Kyoko Takeuchi, Shuji Ozaki and Toshio Matsumoto :
Bone marrow stromal cells attenuate gama delta T,
第72回日本血液学会, Sep. 2010.
104. Shingen Nakamura, Masahiro Abe, Cui Qu, Keiichiro Watanabe, Akishige Ikegame, Masahiro Hiasa, 三木 浩和, 中野 綾子, 小田 明日香, 天羽 宏枝, 神野 雅, 原田 武志, Shiroh Fujii, Kumiko Kagawa, Kyoko Takeuchi, Shuji Ozaki and Toshio Matsumoto :
ボルテゾミブによる骨芽細胞分化の促進は過剰な小胞体ストレスによって抑制される,
第28回日本骨代謝学会, Jul. 2010.

Et cetera, Workshop:

1. 梶田 敬介, Shingen Nakamura, 曽我部 公子, 藤野 ひかる, 丸橋 朋子, Shiroh Fujii, Hirokazu Miki, Kumiko Kagawa, Hiroaki Toba and 阿部 正博 :
胸腺腫瘍に合併した赤芽球癆の二例-病態解明へのアプローチ-,
第252回徳島医学会学術集会, Feb. 2016.
2. Ryota Amachi, Masahiro Abe, Keiichiro Watanabe, Kumiko Kagawa, Shiroh Fujii, 原田 武志, Hirokazu Miki, Keiichiro Watanabe, 小野 明日香, Masahiro Hiasa, Eiji Tanaka and Toshio Matsumoto :
骨髄腫の酸性環境はTRAIL受容体発現をエピジェネティックに抑制し,TRAIL抵抗性をもたらす,
第20回徳島骨代謝研究会, Nov. 2013.
3. Masahiro Hiasa, Masahiro Abe, 中野 綾子, Keiichiro Watanabe, Kyoko Takeuchi, Kumiko Kagawa, Hirokazu Miki, Shingen Nakamura, Shiroh Fujii, 原田 武志, Shuji Ozaki, Eiji Tanaka, Kenzo Asaoka and Toshio Matsumoto :
Pimキナーゼの阻害による骨髄腫の進展抑制,
癌と骨病変研究会, Nov. 2011.

Grants-in-Aid for Scientific Research (KAKEN Grants Database @ NII.ac.jp)

  • Suppression of tumor progression in multiple myeloma by osteogenic microenvironment: Elucidation of the molecular pathogenesis of tumor suppressing niche (Project/Area Number: 21K16244 )
  • Elucidation of acidic metabolism in multiple myeloma and the development of novel therapies targeting its acidic microenvironment. (Project/Area Number: 19K17858 )
  • Search by Researcher Number (00618473)